Sharjah faces intense rainfall amid Al Bashayer low-pressure system Sharjah: Powerful convective cloud formations were observed advancing over the waters off Sharjah on Thursday, as part of Al ...

ISLAMABAD: The Higher Education Commission (HEC) on Friday said it has initiated a project to revamp its degree attestation system by integrating cutting-edge blockchain technology. “This pivotal ...

Bariatric surgery is more cost-effective than GLP-1 RAs for obesity treatment, with lower long-term costs and greater weight loss outcomes. The study found that bariatric surgery led to fewer ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

Marking a historic milestone, the U.S. Coast Guard announced Monday the combined interdiction of more than 76,140 pounds of illicit narcotics. The quantity of drugs offloaded at Port Everglades is the ...

Dubai: Heavy rain hit some areas of eastern regions in UAE on Sunday, August 10, at around 4.30 pm, while other parts of the country saw cloudy to partly cloudy skies. Dusty conditions with low ...

Home equity contracts promise no payments but demand high end-term paybacks. Federal regulators warn HECs mirror risky loans from the 2008 housing crash. Rising home values and opaque terms raise long ...

Explore the outreach toolkit, view upcoming screening events, and browse support materials for two NOVA films – Critical Condition: Health in Black America and When Machines Prescribe. In Critical ...

Newark Mayor Ras Baraka appeared in federal court for a status conference Thursday following his arrest outside an Immigration and Customs Enforcement facility last week. Prosecutors confirmed they ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Early phase I data for Revolution Medicines Inc.’s RAS(ON) G12D-selective inhibitor zoldonrasib encouraged both the company and the analysts. Initial study data produced a 61% objective response rate ...